Beijing Sun-Novo Pharmaceutical Research Co 688621.SS · CNY
Health Care · Shanghai · 🇨🇳 China
51.92
-2.48%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Sun-Novo Pharmaceutical Research Co
Its shares trade on Shanghai under the ticker 688621.SS. It has been listed since 21 June 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.22bn and net income of CN¥196.1m. At that date it held total assets of CN¥2.28bn and shareholders' equity of CN¥1.22bn.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. engages in the research and development of pharmaceutical products. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-06-21. The firm's main businesses include comprehensive research and development services in generic drug development, consistency evaluation and innovative drug development. Its services mainly include pharmaceutical research, clinical trials and biological analysis. Pharmaceutical research services include raw materials and preparation process research, quality standards and stability research, etc. Clinical trial services include phase I-IV clinical trial research, Bioequivalency (BE) test research. Biological analysis services include the use of mass spectrometry analysis platform, immunoassay platform, cell analysis platform, molecular biology analysis platform for method development, method validation, biological sample detection research, etc. The firm mainly conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 21 Jun 2021
- Employees
- 1,126
- Website
- sun-novo.com ↗
Leadership
Pay as last reported
- Mr. Qian LiChairman of the Board, since 2020CN¥1.3m
- Mr. Zhijiao ZhangChief Financial Officer
- Mr. Yujing LiuGeneral Manager, Director, since 2020CN¥1.9m
- Mr. Guangtao HaoDeputy General ManagerCN¥873,700
- Mr. Huan LuoDeputy General ManagerCN¥935,000
- Ms. Yan ShaoDeputy General ManagerCN¥739,800
- Mr. Yuanfeng TongDeputy General ManagerCN¥1.2m
- Ms. Liping WeiSecretary of the Board
- Ms. Qiao ChenDirector
- Mr. Wenran LiDirector
- Mr. Ying ZhangDirector
- Mr. Zhuangkun HeIndependent DirectorCN¥60,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Beijing Sun-Novo employs 1,126 full-time employees for comprehensive R&D services.
- The company offers generic drug development and innovative drug development services.
- Beijing Sun-Novo provides clinical trial services from phase I to IV.
Weaknesses
- The firm operates solely in the domestic market of China.
- Beijing Sun-Novo's services include pharmaceutical research and clinical trials.
- The company's main focus is on domestic market operations.
Opportunities
- Beijing Sun-Novo can expand into international markets for pharmaceutical R&D.
- The firm can leverage its mass spectrometry analysis platform for global services.
- Beijing Sun-Novo may grow through innovative drug development opportunities.
Threats
- The domestic market in China faces increasing competition in pharmaceutical R&D.
- Beijing Sun-Novo's reliance on domestic market operations poses a risk.
- The company faces challenges in expanding beyond China's regulatory environment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.